{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-352229","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2026-08-14T20:09:26+00:00","discovered_at":"2026-08-14T20:17:33.330868+00:00","generated_at":"2026-08-14T20:18:09.424382+00:00","sec_items":["8.01","9.01","2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Achieve Life Sciences enters $150M ATM offering with Jefferies for cytisinicline funding","bullets":["Entered Open Market Sale Agreement with Jefferies LLC for up to $150M in common stock ATM sales.","Jefferies receives up to 3.0% commission on gross proceeds; company may suspend or terminate at any time.","Proceeds to fund commercialization of cytisinicline and Phase 3 trial for e-cigarette cessation.","Shares sold under existing Form S-3 registration statement filed Jan 23, 2026; no obligation to sell."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-352229","json":"https://secwatch.observer/filing/0001193125-26-352229.json","markdown":"https://secwatch.observer/filing/0001193125-26-352229.md","text":"https://secwatch.observer/filing/0001193125-26-352229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000119312526352229/0001193125-26-352229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000119312526352229/achv-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:18:09.424382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}